Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Plus Therapeutics Inc (PSTV)

Plus Therapeutics Inc (PSTV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,070
  • Shares Outstanding, K 5,704
  • Annual Sales, $ 4,910 K
  • Annual Income, $ -13,320 K
  • 60-Month Beta 0.65
  • Price/Sales 1.81
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade PSTV with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.57
  • Number of Estimates 1
  • High Estimate -0.57
  • Low Estimate -0.57
  • Prior Year -1.00
  • Growth Rate Est. (year over year) +43.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1450 +44.10%
on 09/09/24
1.7600 -6.25%
on 09/18/24
+0.2900 (+21.32%)
since 08/16/24
3-Month
1.1450 +44.10%
on 09/09/24
2.0700 -20.29%
on 07/17/24
-0.2800 (-14.51%)
since 06/18/24
52-Week
0.9694 +70.21%
on 10/25/23
2.7800 -40.65%
on 11/17/23
+0.3300 (+25.00%)
since 09/18/23

Most Recent Stories

More News
Plus: Q2 Earnings Snapshot

Plus: Q2 Earnings Snapshot

PSTV : 1.6490 (+3.71%)
Biotech Turning Heads For Second Time This Week

This %Biotech company seems to hog the spotlight as of late. We covered a release earlier this week pertaining to a stock buyback program the company is initiating. Now the Austin-based micro cap is at...

PSTV : 1.6490 (+3.71%)
Micro Cap Surges During Premarket Following Share Buyback Announcement

An Austin-based %Biotech company is getting some major attention Monday morning after the company announced that its Board of Directors has approved a share repurchase program with authorization t repurchase...

PSTV : 1.6490 (+3.71%)
Plus Therapeutics to Present Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases

AUSTIN, Texas, July 28, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company...

PSTV : 1.6490 (+3.71%)
Plus Therapeutics to Present at Inaugural Targeted Radiopharmaceuticals Summit

AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company...

PSTV : 1.6490 (+3.71%)
Plus Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

Completed enrollment of Cohort 1 in ReSPECT-LM Phase 1/2a dose escalation trial of 186RNL for Leptomeningeal Metastases On track to complete key...

PSTV : 1.6490 (+3.71%)
Plus Therapeutics to Announce Second Quarter 2022 Financial Results and Host Conference Call on July 21, 2022

AUSTIN, Texas, July 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company...

PSTV : 1.6490 (+3.71%)
Plus Therapeutics Successfully Completes Key Milestone for cGMP Manufacture of Lead Investigational Radiotherapeutic

Completes technology transfer and initiates cGMP manufacturing for critical Rhenium-186 NanoLiposome (186RNL) drug product intermediate On track to...

PSTV : 1.6490 (+3.71%)
Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial

Biocept’s CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden in leptomeningeal metastasis (LM) of the central...

PSTV : 1.6490 (+3.71%)
Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1/2a Trial

Rhenium-186 NanoLiposome (186RNL) Targeted Radiotherapeutic successfully delivered without dose limiting toxicities in initial cohort Next step: Data...

PSTV : 1.6490 (+3.71%)

Business Summary

Plus Therapeutics Inc. is a clinical-stage pharmaceutical company. It engages in developing treatments for cancer and other diseases primarily in the United States. The company's product candidate consists of DocePLUS which are in clinical stage. Plus Therapeutics Inc., formerly known as Cytori Therapeutics...

See More

Key Turning Points

3rd Resistance Point 1.6965
2nd Resistance Point 1.6433
1st Resistance Point 1.6166
Last Price 1.6490
1st Support Level 1.5367
2nd Support Level 1.4835
3rd Support Level 1.4568

See More

52-Week High 2.7800
Fibonacci 61.8% 2.0884
Fibonacci 50% 1.8747
Fibonacci 38.2% 1.6610
Last Price 1.6490
52-Week Low 0.9694

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar